Showing posts with label Jim. Show all posts
Showing posts with label Jim. Show all posts
Friday, August 18, 2017
Red Sox Select Pitcher Tanner Houck in First Round of MLB Draft
Through nearly seven years as head of capital markets for Laidlaw & Company, James "Jim" Ahern has grown the investment bank to national recognition with offices in New York, Boston, San Francisco, and London. When he isn't busy with his work at Laidlaw, James Ahern enjoys following his favorite Major League Baseball (MLB) team, the Boston Red Sox.
The 40-round 2017 MLB Amateur Draft was held in June and the Red Sox had the 24th overall selection. Boston used that pick to choose hard-throwing right-handed pitcher Tanner Houck, who the organization anticipates becoming a member of the starting rotation in the not-so-distant future. One of the hardest throwers available in the draft, Houck regularly reaches 96 miles per hour (mph) with his fastball and has reached 98 mph on occasion.
A native of Collinsville, Illinois, Houck spent this past season at the University of Missouri, where he posted a 4-7 record and a 3.33 earned run average (ERA) to go along with 95 strikeouts in 94.66 innings. He was signed by the Red Sox and has since started four games for the team's A-ball affiliate the Lowell Spinners of the New York-Pennsylvania League. To date, he has a 3.68 ERA and has given up just four hits while striking out nine batters in 7.33 innings.
Wednesday, August 2, 2017
Gemphire Therapeutics’ Clinically Demonstrated Gemcabene Medication
As the head of capital markets and the managing partner at Laidlaw & Company in New York, James Ahern focuses on an expanding healthcare investment market. James (Jim) Ahern and the Laidlaw team have successfully engineered initial public offerings for Therapix Biosciences, Cerecor, and Gemphire Therapeutics, among others.
Gemphire, a Michigan-based clinical-stage biopharmaceutical enterprise, focuses on the commercialization of treatments for patients living with nonalcoholic steatohepatitis, dyslipidemia, and cardiometabolic disorders. Gemcabene, licensed from Pfizer in 2011, is a promising oral drug candidate that effectively decreases inflammation, LDL-C, and fat in the form of triglycerides.
To date, nearly 200 clinical gemcabene Phase 1 and Phase 2 trials have been accomplished, both as a monotherapy and in tandem with statins of various dosages. The market size for this drug, which has been demonstrated as safe and effective, is estimated at 20 million patients and $33 billion by 2025.
Friday, March 17, 2017
A Handful of the Best Restaurants on Nantucket
Possessing extensive experience in finance, James "Jimmy" Ahern Laidlaw is managing partner and head of capital markets with Laidlaw & Company. Outside of work, Jimmy Ahern Laidlaw enjoys taking trips to Nantucket, especially for the excellent restaurants that exist on the island.
One of the best restaurant on the island is Cru Oyster Bar, which serves excellent lobster rolls and boosts a full raw bar. Located in the middle of the Nantucket Boat Basin, Cru also provides diners with incredible vantage points.
Another great choice is The Pearl, which uses local seafood and regional heritage meats to put a unique spin on Eastern dishes. One of the must-try dishes at the restaurant is the Salt & Pepper Wok Fried Lobster.
Galley Beach, located right on the sand, is another classic choice. Dining her transports people to the Caribbean, especially if they dine al fresco during the sunset. The restaurant offers casual lunches and exquisite three-course dinners.
Located in the heart of the island, American Season boasts a quintessential seasonal menu. The restaurant remains one of the oldest on Nantucket and is known for its fun takes on classic American cuisine.
Subscribe to:
Posts (Atom)